Framingham Risk Score Calculator

Framingham Risk Score Calculator for Cardiology. For the 10-year hard-CHD (ATP III) version, results are conventionally banded as low (under 10 percent), intermediate (10 to 20 percent), and high (20 percent or greater), with the intermediate band being where additional testing such as coronary artery calcium scoring most changes management. The general-CVD version yields a higher absolute percentage because it counts stroke, PAD, and heart failure as well, so a 20 percent CVD risk is not equivalent to a 20 percent CHD risk and the two must not be interchanged. Higher scores escalate the intensity of lipid lowering, blood-pressure targets, aspirin consideration, and follow-up frequency. The score is a starting point for a shared risk conversation, not an automatic prescription trigger.

How this calculator works

The Framingham Risk Score estimates an individual's absolute probability of a cardiovascular event over a defined follow-up window using sex-specific multivariable Cox proportional-hazards equations derived from the Framingham Heart Study cohort. Points (or beta-weighted terms) are assigned to age, total and HDL cholesterol, systolic blood pressure with a separate weighting for treated versus untreated hypertension, smoking status, and diabetes; the summed score maps to a percentage risk. The widely used 2008 general CVD version predicts a first hard atherosclerotic event (coronary heart disease, stroke, peripheral artery disease, or heart failure) over 10 years, whereas the older 1998 Wilson/ATP III version predicts hard coronary heart disease only. A non-laboratory variant substitutes BMI for lipid values so the score can be computed without a blood draw.

When to use this calculator

Use it to stratify primary-prevention adults roughly 30 to 74 (or 20 to 79 in the general-CVD version) who are free of known cardiovascular disease, to inform statin and blood-pressure treatment discussions. It should not be applied to patients with established ASCVD, prior MI or stroke, diabetes with target-organ damage, LDL above about 190 mg/dL, or chronic kidney disease, all of whom are already high-risk by default. It was derived in a predominantly white middle-aged cohort, so it miscalibrates in South Asian, Black, and older populations; the pooled cohort equations or SCORE2 are often preferred there.

Inputs used

  • Age
  • Sex
  • Total cholesterol
  • HDL cholesterol
  • Systolic blood pressure
  • Blood pressure treatment
  • Smoking
  • Diabetes

Clinical interpretation

For the 10-year hard-CHD (ATP III) version, results are conventionally banded as low (under 10 percent), intermediate (10 to 20 percent), and high (20 percent or greater), with the intermediate band being where additional testing such as coronary artery calcium scoring most changes management. The general-CVD version yields a higher absolute percentage because it counts stroke, PAD, and heart failure as well, so a 20 percent CVD risk is not equivalent to a 20 percent CHD risk and the two must not be interchanged. Higher scores escalate the intensity of lipid lowering, blood-pressure targets, aspirin consideration, and follow-up frequency. The score is a starting point for a shared risk conversation, not an automatic prescription trigger.

Worked example

A 55-year-old male non-diabetic smoker with total cholesterol 220 mg/dL, HDL 40 mg/dL, and untreated systolic BP 140 mmHg accumulates points for age, the lipid ratio, elevated systolic pressure, and smoking. In the ATP III coronary point system this sums to roughly 16 points, corresponding to an approximately 20 percent 10-year hard-CHD risk, placing him in the high-risk category and supporting moderate-to-high-intensity statin therapy plus smoking cessation and blood-pressure control.

Limitations and safety notes

It systematically overestimates risk in contemporary and lower-risk populations (statin and antihypertensive use, declining smoking rates) and underestimates it in high-risk ethnic groups such as South Asians. It ignores family history of premature CVD, triglycerides, LDL particle burden, Lp(a), inflammatory markers, renal function, and socioeconomic factors, so a "low" score can mask genuinely elevated risk. Age dominates the equation, meaning young adults with severe single risk factors are frequently under-scored while otherwise healthy elderly patients are pushed into treatment bands. The non-laboratory BMI-based variant trades accuracy for convenience and should be a screening fallback only.

Frequently asked questions

What is the difference between the 1998 and 2008 Framingham scores?

The 1998 Wilson/ATP III score predicts 10-year risk of hard coronary heart disease (MI and coronary death) only. The 2008 D'Agostino general-CVD score predicts a broader first cardiovascular event including stroke, peripheral artery disease, and heart failure, so its percentages run higher and the two are not interchangeable.

Why does treated hypertension score differently from untreated?

The equations assign a higher weight to a given systolic pressure when the patient is on antihypertensive treatment, because being medicated to that level signals underlying disease and residual risk beyond the current reading alone.

Can I use it in patients with diabetes?

The original coronary version treats diabetes as a risk factor within the equation, but many guidelines regard diabetes with end-organ damage as a CHD risk-equivalent that already warrants high-risk management, so the score adds little in those patients and can understate their risk.

Why do guidelines increasingly favor the pooled cohort equations or SCORE2 instead?

Those newer tools were derived and calibrated in more diverse and contemporary populations and incorporate race (PCE) or region-specific calibration (SCORE2), addressing Framingham's tendency to miscalibrate outside a white middle-aged cohort.

How should an intermediate-risk result change management?

An intermediate 10-year result (roughly 10 to 20 percent) is where risk-enhancing factors and coronary artery calcium scoring are most useful; a high calcium score reclassifies upward toward statin therapy, while a zero score may support deferral in selected patients.

References

  • Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837-47. PMID: 9603539.
  • D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. PMID: 18212285.
  • National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. PMID: 12485966.

Editorial review and citation methodology

Reviewed by the Quick Medical Calculator Editorial Team. Last reviewed: March 23, 2026. The review checks calculator inputs, intended population, interpretation, limitations, and source alignment.

  • Prefer original validation studies for scoring systems and prediction tools.
  • Use current specialty society guidance, transplant allocation policy, public health guidance, or regulator resources when they govern clinical use.
  • Include limitations and safety notes when a calculator is population-specific, context-dependent, or unsuitable as a standalone decision tool.

Related reviewed calculators